Vamifeport History and Updates

12 events · 2021 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
12
Trial Milestones
0
Pivotal Publications
Vamifeport — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications2022202320242025202620272028Trial: NCT07332091 2026-01-22 → 2028-03-06 (primary completion)Trial: NCT06996184 2025-05-27 → 2025-07-01 (primary completion)Trial: NCT06726863 2024-11-22 → 2025-01-27 (primary completion)Trial: NCT05077436 2021-10-14 → 2021-12-29 (primary completion)today (2026-06-03)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-03Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Vamifeport since 2021, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT07332091
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

Past events

2026
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07332091
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
2025
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06996184
Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06996184
Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06726863
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
2024
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06726863
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults
2021
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT05077436
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT05077436
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.